Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” second-quarter ...

Greenhaven Road Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the ...

Cellebrite DI ( ($CLBT) ) just unveiled an announcement. On August 15, 2025, Cellebrite DI Ltd. announced its upcoming Annual General Meeting of ...

Lake Street analyst Eric Martinuzzi lowered the firm’s price target on Cellebrite (CLBT) to $22 from $24 and keeps a Buy rating on the shares.

Cellebrite experienced solid growth in Q2 2025, exceeding expectations for sales and earnings. Signs of a rebound are encouraging.

Detailed price information for Cellebrite Di Ltd (CLBT-Q) from The Globe and Mail including charting and trades.

Cellebrite (CLBT) boasts strong growth potential with robust financials, digital forensics leadership, and a durable moat.

We came across a bullish thesis on Cellebrite DI Ltd. on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on CLBT.

View the latest Cellebrite DI Ltd. (CLBT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Learn about the executive team and board of directors at Cellebrite DI Ltd (CLBT:XNAS) and review their bios and compensation over the latest fiscal years.